Details

Autor(en) / Beteiligte

• Naples, James G.
• Rice‐Narusch, Wyatt
• Watson, Nathan W.
• Ghulam‐Smith, Melissa
• Holmes, Sean
• Li, Daqing
• Jalisi, Scharukh

Titel

Ototoxicity Review: A Growing Number of Non–Platinum‐Based Chemo‐ and Immunotherapies

Ist Teil von

• Otolaryngology-head and neck surgery, 2023-04, Vol.168 (4), p.658-668

Ort / Verlag

England

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Objective To raise awareness of the growing list of non–platinum‐based chemo‐ and immunotherapeutic agents that have been associated with ototoxicity and to introduce the possible mechanism of ototoxicity of these agents. Data Sources PubMed, Embase, and Web of Science. Review Methods A systematic review was performed following the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta‐analyses). PubMed, Embase, and Web of Science databases were searched for published reports of ototoxicity from non–platinum‐based chemo‐ and immunotherapeutic agents in adult and pediatric patients. Therapies that utilized any platinum‐based agent were excluded. Conclusions Ototoxicity from non–platinum‐based chemo‐ and immunotherapies is an evolving problem. There were 54 reports—39 case reports and 15 cohort studies—documenting ototoxicity from 7 agents/combination therapies. Of these reports, 37 (69%) were published within the last 15 years (after 2005). No recovery of hearing was documented in 21 of 56 cases (38%). Pretreatment audiograms were uncommon (19/54 studies, 35%), despite documented ototoxic associations. Implications for Practice There is a growing number of novel, ototoxic, non–platinum‐based chemo‐ and immunotherapeutic agents with various potential mechanisms of action. Otolaryngologists will need to prioritize awareness of these agents. This growing list of agents, many of which have reversible effects, suggest a need for standardized ototoxicity monitor protocols so that appropriate and timely management options can be implemented.